Cochrane Abstracts
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation. Accessed January 13, 2025.
Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation
Anti‐GD2 Antibody‐containing Immunotherapy Postconsolidation Therapy for People With High‐risk Neuroblastoma Treated With Autologous Haematopoietic Stem Cell Transplantation [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2025 January 13]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Anti‐GD2 antibody‐containing immunotherapy postconsolidation therapy for people with high‐risk neuroblastoma treated with autologous haematopoietic stem cell transplantation
ID - 434652
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434652/all/Anti‐GD2_antibody‐containing_immunotherapy_postconsolidation_therapy_for_people_with_high‐risk_neuroblastoma_treated_with_autologous_haematopoietic_stem_cell_transplantation
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
